{"title":"Ebola Virus: Promising Vaccine Candidates","authors":"Reema Sameem, S. Dias","doi":"10.17140/vroj-2-106","DOIUrl":null,"url":null,"abstract":"Ebola Virus Disease is among the deadliest viral diseases. The field of Ebola vaccine development has progressed over the years with numerous candidates in advanced stages of clinical development. Currently, there is no licensed vaccine against Ebola virus. This review aimed to discuss the promising Ebola vaccine candidates focusing on vaccines against ebola viruses in particular against Zaire ebola virus (ZEBOV). Although DNA vaccines have been evaluated in Phase I clinical studies, it demonstrates low immunogenicity. Thus far, the most successful vaccine platforms are the recombinant viruses including, replicating vesicular stomatitis virus (rVSV) and chimpanzee adenovirus 3 (ChAd3). The successful trials attests that rVSV vaccines will be submitted for licensing in the near future.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccination research : open journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17140/vroj-2-106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
Ebola Virus Disease is among the deadliest viral diseases. The field of Ebola vaccine development has progressed over the years with numerous candidates in advanced stages of clinical development. Currently, there is no licensed vaccine against Ebola virus. This review aimed to discuss the promising Ebola vaccine candidates focusing on vaccines against ebola viruses in particular against Zaire ebola virus (ZEBOV). Although DNA vaccines have been evaluated in Phase I clinical studies, it demonstrates low immunogenicity. Thus far, the most successful vaccine platforms are the recombinant viruses including, replicating vesicular stomatitis virus (rVSV) and chimpanzee adenovirus 3 (ChAd3). The successful trials attests that rVSV vaccines will be submitted for licensing in the near future.